度普利尤单抗治疗特应性皮炎患者的面部红斑——形态与病因的描述性研究
多中心前瞻性队列研究纳入162例接受度普利尤单抗治疗的特应性皮炎患者,137例(84.6%)治疗前已存在面部皮炎,其中121例(88.3%)治疗后改善、9例(6.6%)无变化、7例(4.3%)加重;25例无治疗前活动性面部皮炎者中6例(24%)出现新发面部红斑。加重组86%和新发组67%有面部外用糖皮质激素使用史,两组临床表现和分布相似。
要点
- 84.6%(137/162)患者度普利尤单抗治疗前已有面部皮炎,其中88.3%(121/137)治疗后改善。
- 7例(4.3%)面部皮炎加重,25例无治疗前活动性面部皮炎者中6例(24%)新发面部红斑。
- 加重组86%和新发组67%有面部外用糖皮质激素使用史,部分患者红斑应考虑激素撤退诊断。
核心结论
- 绝大多数接受度普利尤单抗治疗的特应性皮炎患者面部皮炎改善,小部分出现新发或加重。
- 该不良事件机制尚不清楚,但部分患者红斑应考虑激素撤退作为诊断。
研究设计与样本
- 多中心前瞻性队列研究,于2020年1月1日至2020年12月31日开展。
- 共162例接受度普利尤单抗治疗的特应性皮炎患者完成问卷并由皮肤科医生评估。
主要发现
- 162例中137例(84.6%)报告度普利尤单抗治疗前已存在面部皮炎。
- 137例治疗前有面部皮炎者中,121例(88.3%)报告面部皮炎改善,9例(6.6%)无变化,7例(4.3%)加重(加重组)。
- 25例报告治疗前无活动性面部皮炎者中,6例(24%)在开始度普利尤单抗治疗后出现新发面部红斑(新发组)。
- 加重组86%和新发组67%有面部外用糖皮质激素使用史。
- 两组临床表现和分布相似,差异很少。
临床怎么用
- 原文结论指出,部分患者红斑应考虑激素撤退作为诊断。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The development of dermatitis on face and neck, which was not described in phase 3 clinical trials, has been reported in the literature in patients treated with dupilumab. Little is known regarding the causes or defining features of the facial dermatitis. OBJECTIVES: We conducted surveys of consecutive patients with AD on dupilumab to describe its clinical features, morphology and aetiology. METHODS: A multi-centre prospective cohort study was conducted from 1 January 2020, to 31 December 31 2020. A total of 162 patients under dupilumab treatment were asked to complete a questionnaire and patients were evaluated by dermatologists. RESULTS: Of all 162 patients, 137 (84.6%) patients reported pre-existing facial dermatitis prior to dupilumab therapy. One hundred and twenty-one (88.3%) patients with pre-existing facial dermatitis reported improvement of their facial dermatitis with dupilumab therapy, nine (6.6%) patients reported no change after the treatment and seven (4.3%) patients of them got worse after the treatment (exacerbation group). Of 25 patients who reported no pre-existing active facial dermatitis, six (24%) patients reported new-onset facial erythema after the starting dupilumab therapy (new-onset group). A large proportion of the patients in both the exacerbation (86%) and new-onset groups (67%) had a history of facial TCS use. Both groups showed similar clinical manifestations and distribution with few differences. CONCLUSIONS: The vast majority of patients treated with dupilumab in academic institutions from Korea and the United States experienced improvement in their facial dermatitis with dupilumab therapy. A small proportion of patients had new onset and exacerbation. Although the mechanisms of this adverse event remain unclear, steroid withdrawal should be considered as a diagnosis of the erythema in some patients.
引用
- Ahn J, Lee DH, Na CH, et al. Facial erythema in patients with atopic dermatitis treated with Dupilumab - a descriptive study of morphology and Aetiology. J Eur Acad Dermatol Venereol. 2022. PMID: 35695074. doi:10.1111/jdv.18327
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。